Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henrik Daub

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Molecular Cell|May 1, 2012
DNA damage response: multilevel proteomics gains momentumHenrik Daub
Biochimica Et Biophysica Acta|October 4, 2005
Characterisation of kinase-selective inhibitors by chemical proteomicsHenrik Daub
ACS Chemical Biology|December 5, 2014
Quantitative proteomics of kinase inhibitor targets and mechanismsHenrik Daub
Cell Cycle (Georgetown, Tex.)|January 31, 2004
Proteomic analysis of kinase inhibitor selectivity and functionKlaus Godl, Henrik Daub
Nature Reviews. Drug Discovery|December 2, 2004
Strategies to overcome resistance to targeted protein kinase inhibitorsHenrik Daub, Katja Specht, Axel Ullrich
The Journal of Biological Chemistry|February 21, 2003
Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitorsStephanie Blencke, Axel Ullrich, Henrik Daub
Journal of Proteomics|November 26, 2011
Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cellsChristoph Weber, Thiemo B Schreiber, Henrik Daub
Molecular & Cellular Proteomics : MCP|July 20, 2010
Glycoprotein capture and quantitative phosphoproteomics indicate coordinated regulation of cell migration upon lysophosphatidic acid stimulationNina Mäusbacher, Thiemo B Schreiber, Henrik Daub
Molecular & Cellular Proteomics : MCP|August 5, 2009
Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomicsCuiping Pan, Jesper V Olsen, Henrik Daub, et al.
Molecular & Cellular Proteomics : MCP|February 11, 2004
Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitorsDirk Brehmer, Klaus Godl, Birgit Zech, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Molecular Cell|May 1, 2012
DNA damage response: multilevel proteomics gains momentumHenrik Daub
Biochimica Et Biophysica Acta|October 4, 2005
Characterisation of kinase-selective inhibitors by chemical proteomicsHenrik Daub
ACS Chemical Biology|December 5, 2014
Quantitative proteomics of kinase inhibitor targets and mechanismsHenrik Daub
Cell Cycle (Georgetown, Tex.)|January 31, 2004
Proteomic analysis of kinase inhibitor selectivity and functionKlaus Godl, Henrik Daub
Nature Reviews. Drug Discovery|December 2, 2004
Strategies to overcome resistance to targeted protein kinase inhibitorsHenrik Daub, Katja Specht, Axel Ullrich
The Journal of Biological Chemistry|February 21, 2003
Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitorsStephanie Blencke, Axel Ullrich, Henrik Daub
Journal of Proteomics|November 26, 2011
Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cellsChristoph Weber, Thiemo B Schreiber, Henrik Daub
Molecular & Cellular Proteomics : MCP|July 20, 2010
Glycoprotein capture and quantitative phosphoproteomics indicate coordinated regulation of cell migration upon lysophosphatidic acid stimulationNina Mäusbacher, Thiemo B Schreiber, Henrik Daub
Molecular & Cellular Proteomics : MCP|August 5, 2009
Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomicsCuiping Pan, Jesper V Olsen, Henrik Daub, et al.
Molecular & Cellular Proteomics : MCP|February 11, 2004
Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitorsDirk Brehmer, Klaus Godl, Birgit Zech, et al.
Pageof 5